Wells Fargo & Company Issues Positive Forecast for NeuroPace (NASDAQ:NPCE) Stock Price

NeuroPace (NASDAQ:NPCE) had its price target boosted by Wells Fargo & Company from $15.00 to $16.00 in a report published on Wednesday,Benzinga reports. The firm currently has an overweight rating on the stock.

Other equities analysts have also issued research reports about the stock. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price target on shares of NeuroPace in a research report on Wednesday. Leerink Partners reaffirmed an “outperform” rating and set a $19.00 price objective on shares of NeuroPace in a report on Wednesday. Zacks Research downgraded shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NeuroPace in a report on Wednesday, October 8th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.33.

NeuroPace Price Performance

NPCE opened at $12.98 on Wednesday. The firm has a market cap of $429.38 million, a P/E ratio of -17.08 and a beta of 1.90. The firm has a 50-day moving average of $10.21 and a 200 day moving average of $10.84. The company has a debt-to-equity ratio of 3.02, a quick ratio of 4.51 and a current ratio of 5.47. NeuroPace has a fifty-two week low of $6.63 and a fifty-two week high of $18.98.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $27.35 million during the quarter, compared to analyst estimates of $24.64 million. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 139.13%. NeuroPace has set its FY 2025 guidance at EPS. On average, research analysts expect that NeuroPace will post -1 EPS for the current year.

Institutional Investors Weigh In On NeuroPace

A number of institutional investors and hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. lifted its holdings in shares of NeuroPace by 83.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock worth $27,000 after buying an additional 1,118 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of NeuroPace by 86.0% in the second quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock worth $30,000 after buying an additional 1,239 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of NeuroPace by 15.2% in the first quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock worth $212,000 after buying an additional 2,267 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in shares of NeuroPace by 72.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company’s stock worth $71,000 after buying an additional 2,668 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of NeuroPace by 7.4% in the first quarter. Charles Schwab Investment Management Inc. now owns 39,237 shares of the company’s stock worth $482,000 after purchasing an additional 2,700 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.